About Ritu Lal

Dr. Lal is CEO and Co-Founder of GEn1E Lifesciences Inc (www.gen1e.com). GEn1E is a clinical-stage biotech company accelerating novel, next-generation immunomodulatory therapies for Rare & Inflammatory diseases.

She has over 20 years of experience in Biotech/Pharma companies. Her passion is to bring healthcare products to patients in a cost-effective and efficient manner. In her role as a Senior Executive, she led Preclinical and Clinical Development teams. She has taken compounds from Discovery to Regulatory Approval and has filed more than 15 Investigational New Drug Applications (IND) in disease areas of neurology, inflammation, virology, pain, and oncology. Two compounds have received New Drug Application (NDA) approvals from the US FDA and Ministry of Health and Welfare, Japan (Kaletra for the treatment of HIV and Horizant (Regnite in Japan) for Restless Legs Syndrome (RLS) and Post Herpetic Neuralgia (PHN)).

Dr. Lal has a doctorate in Pharmaceutical Sciences and Pharmacology from the University of Maryland and a Master’s degree in Pharmacology from the University of Arizona. Dr. Lal has over 60 publications, book chapters, and presentations. She received a Master’s in Management from Stanford University’s MSx (Sloan) Program.